Pheochromocytoma Surgery — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Pheochromocytoma is a catecholamine (adrenaline, noradrenaline, dopamine)-secreting tumour arising from chromaffin cells of the adrenal medulla (inner layer of the adrenal gland) — a rare but surgically curable cause of secondary hypertension. The surgical removal (adrenalectomy) of a pheochromocytoma is the definitive curative treatment and is considered a high-complexity operation requiring meticulous preoperative pharmacological preparation and intraoperative anaesthetic management to prevent life-threatening hypertensive crises — the hallmark danger of these tumours. Uncontrolled catecholamine release during tumour handling causes acute, severe hypertension, cardiac arrhythmias, pulmonary oedema, and stroke. The standard surgical approach is laparoscopic transperitoneal or retroperitoneal adrenalectomy for tumours under 6–8 cm, performed by experienced endocrine or urological surgeons in specialist centres. Open surgery is reserved for large, invasive, or malignant tumours, bilateral disease, or recurrence. Approximately 10% of pheochromocytomas are malignant, 10% are bilateral, 10% occur in extra-adrenal locations (paraganglioma), and 10% occur in children — the classical '10% rule' (though actual frequencies vary). A significant proportion (30–40%) are associated with germline mutations in genes including VHL, RET, SDHB, SDHD, NF1, and others, necessitating genetic testing for all patients.

Surgery is indicated for all patients with confirmed pheochromocytoma after appropriate preoperative alpha-adrenergic blockade, regardless of tumour size or functional status. The diagnosis is established biochemically (elevated plasma free metanephrines and normetanephrines — sensitivity 97%, specificity 85% per Endocrine Society guidelines; or 24-hour urine metanephrines and catecholamines) followed by anatomical localisation using CT or MRI of the abdomen. Functional imaging (MIBG scintigraphy or Ga-DOTATATE PET) is used for suspected extra-adrenal disease, metastatic disease workup, and pre-surgical mapping. Classic symptoms include episodic hypertension (paroxysmal hypertensive crises), headache, palpitations, diaphoresis (sweating), and pallor — the 'hypertensive triad' of headache, palpitations, and sweating in a hypertensive patient has high specificity. Sustained hypertension (rather than paroxysmal) may occur in noradrenaline-secreting tumours. Emergency surgery for acutely decompensating pheochromocytoma — thyroid storm-equivalent catecholamine crisis — requires immediate alpha-blockade (phentolamine IV) and intensive care stabilisation before emergency theatre. All patients with pheochromocytoma should have germline genetic testing and family cascade screening due to the high rate of hereditary mutations.

Preoperative alpha-blockade for 10–14 days before surgery is mandatory: phenoxybenzamine (non-competitive, irreversible alpha-blocker) 10–20 mg twice daily, titrated to mild postural hypotension, is standard. Doxazosin is an alternative. Beta-blockade (propranolol or atenolol) is added only AFTER adequate alpha-blockade to prevent reflex tachycardia — never before, as unopposed alpha-stimulation causes hypertensive crisis. Liberal salt and fluid intake corrects the volume depletion of chronic catecholamine excess. Under general anaesthesia with continuous invasive arterial monitoring, the patient is positioned for laparoscopic transperitoneal adrenalectomy (lateral decubitus) or retroperitoneoscopic adrenalectomy (prone). Haemodynamic monitoring includes arterial line, central venous line, and continuous cardiac monitoring — prepared vasoactive agents (sodium nitroprusside, magnesium sulphate, phentolamine) manage intraoperative hypertensive surges during tumour manipulation; noradrenaline infusion manages hypotension after tumour removal. The adrenal gland and tumour are mobilised with minimal direct manipulation, vessels are controlled with clips and energy devices, and the specimen retrieved intact in a retrieval bag. The adrenal vein is ligated early to minimise catecholamine release during dissection. Blood pressure typically falls dramatically upon tumour vessel ligation — the anaesthetic team manages this critical transition with vasopressor support. Intraoperative anaesthetic management is critical: arterial line monitoring, vasodilator infusions (phentolamine, nitroprusside) for hypertensive crises during tumour handling, and vasopressor support (noradrenaline, vasopressin) for rebound hypotension after ligation of adrenal veins. After tumour removal, blood pressure usually normalises rapidly. Surgical duration is 1–3 hours for laparoscopic adrenalectomy and 2–4 hours for open surgery. Intraoperative cardiac monitoring with echocardiography may be required for suspected catecholamine-induced cardiomyopathy (takotsubo pattern).

Surgical resection of pheochromocytoma is curative in 95%+ of patients with benign, sporadic disease. Hypertension resolves or significantly improves in 75–80% of patients post-operatively — eliminating or reducing antihypertensive medication requirements. The cardiovascular risk associated with chronic uncontrolled catecholamine excess (hypertensive cardiomyopathy, arrhythmia, stroke) is definitively eliminated. Laparoscopic adrenalectomy reduces hospital stay to 2–3 days (versus 7–10 days for open surgery), reduces blood loss by 50–70%, reduces analgesic requirements, and allows return to normal activities within 2–4 weeks. Robotic adrenalectomy (da Vinci system) offers 3D magnified visualisation in the retroperitoneal or transperitoneal approach, with improved ergonomics for precise dissection near adrenal veins and vena cava. Laparoscopic outcomes are equivalent to open surgery in experienced centres with significantly lower morbidity — established in multiple prospective comparative studies. Early diagnosis through genetic screening of family members allows prophylactic adrenalectomy before symptomatic disease develops in VHL, SDHB, and MEN2 kindreds. In India, laparoscopic adrenalectomy for pheochromocytoma is available at specialist centres including AIIMS, Tata Memorial, CMC Vellore, at approximately INR 1,50,000–3,00,000 (USD 1,800–3,600), versus USD 25,000–50,000 in the USA.

Pheochromocytoma surgery carries higher risk than standard laparoscopic adrenalectomy due to the catecholamine-related haemodynamic instability. Intraoperative hypertensive crisis (systolic BP over 200 mmHg) despite preoperative alpha-blockade occurs in 25–50% of patients and is managed with sodium nitroprusside, phentolamine, or magnesium sulphate boluses — requiring an experienced anaesthetic team familiar with pheochromocytoma management. Post-resection hypotension (from volume depletion, receptor hypersensitivity, and sudden catecholamine withdrawal) is managed with vasopressor infusion (noradrenaline) and fluid resuscitation — may persist 12–48 hours post-operatively. Persistent hypoglycaemia from reactive hyperinsulinaemia after catecholamine withdrawal requires dextrose supplementation. General surgical risks include haemorrhage from the short adrenal vein (adjacent to the inferior vena cava on the right), splenectomy or diaphragm injury (left adrenalectomy), bowel injury, adjacent organ injury, and wound complications. For bilateral adrenalectomy, Addisonian crisis (acute adrenal insufficiency) is a lifelong risk requiring permanent corticosteroid replacement therapy (hydrocortisone and fludrocortisone). Malignant pheochromocytoma (approximately 10%) — associated with SDHB mutation in particular — requires oncological surveillance and may need additional treatments including MIBG therapy or chemotherapy.

Post-operatively, intensive monitoring in a high-dependency unit (HDU) or ICU for 12–24 hours manages haemodynamic instability, hypoglycaemia, and vasopressor weaning. Blood pressure is checked frequently — persistent hypertension post-operatively may indicate residual tumour, incomplete resection, or essential hypertension and is investigated before discharge. Hospital discharge is typically on day 2–3 after uncomplicated laparoscopic adrenalectomy. Post-operative analgesic requirements are lower with laparoscopic approach — paracetamol and ibuprofen are usually sufficient. Return to light activities at 1 week; return to work at 2–3 weeks; strenuous exercise from 4–6 weeks. Biochemical cure assessment — plasma or urine metanephrines — is measured at 6 weeks post-operatively. A normal result defines biochemical cure. Annual surveillance with plasma metanephrines is recommended for 10 years (ENSAT guidelines) due to late recurrence potential. Genetic testing result determines surveillance protocol: VHL patients require abdominal MRI every 1–2 years; SDHB mutation carriers require annual total-body MRI given high malignant potential. Beta-blockers and calcium channel blockers used preoperatively are usually discontinued post-operatively once blood pressure normalises. Patients with bilateral adrenalectomy receive lifelong oral hydrocortisone (10–20 mg/day) and fludrocortisone (0.1 mg/day) with dose doubling during illness — a sick day rules card is provided.